Is Femasys going out of business?

FEMASYS INC (FEMY) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

FEMASYS INC (FEMY) scores 16 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: FCF margin: -1374.47%

Five questions, kept separate

Survival - Critical

Under 1 mo of estimated runway from 2026-06-30, based on $1.4M of cash and short-term investments against $31.6M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Demanding

0.7% net-cash backing support a demanding pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• FCF margin: -1374.47%
• Debt / Equity: -0.04x (Net Cash)
• ROIC: -491.14%
• Filing event risk: Going-Concern Warning (-8 pts)
• Cash Runway (years): 0.05y
• Revenue CAGR (3Y): 23.88%
• Revenue growth YoY: -18.92% (YoY)
• Return on Assets: -95.76%
• Cash Burn Deceleration: -147.67% QoQ improvement (Worsening)
• Price / Sales: 10.2x (see Valuation)
• Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-08-14.

Price as of 2026-09-07.